Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo - Wikidata - thesis-toulmin - TriplyDB

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

http://www.wikidata.org/entity/Q28360110

about

Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth Ongoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray?Transcriptome markers of viral persistence in naturally-infected andes virus (bunyaviridae) seropositive long-tailed pygmy rice rats The SCFCdc4 ubiquitin ligase regulates calcineurin signaling through degradation of phosphorylated Rcn1, an inhibitor of calcineurin.Regulation of the phosphatase PP2B by protein-protein interactions Calcineurin-independent regulation of plasma membrane Ca2+ ATPase-4 in the vascular smooth muscle cell cycle Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice Action mechanism of fuzheng fangai pill combined with cyclophosphamide on tumor metastasis and growth.Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo.MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy Calcineurin inhibition and cardiac hypertrophy: a matter of balance.TRPC3 contributes to regulation of cardiac contractility and arrhythmogenesis by dynamic interaction with NCX1.Calcineurin and hypertrophic heart disease: novel insights and remaining questions.Mixed signals in heart failure: cancer rules.Calcineurin and cardiac hypertrophy: where have we been? Where are we going?Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo Molecular mechanisms of inherited cardiomyopathies.Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity : a proteomic approach.Carvedilol reverses cardiac insufficiency in AKAP5 knockout mice by normalizing the activities of calcineurin and CaMKII.Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells AKAPs: the architectural underpinnings of local cAMP signaling.Targeting calcineurin and associated pathways in cardiac hypertrophy and failure.Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research.Anchoring proteins as regulators of signaling pathways.Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators Genetic approaches for changing the heart and dissecting complex syndromes.Ca2+-operated transcriptional networks: molecular mechanisms and in vivo models.Designing heart performance by gene transfer.Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells.Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1.Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload.Left ventricular hypertrophy among black hypertensive patients: focusing on the efficacy of angiotensin converting enzyme inhibitors Mapping the protein phosphatase-2B anchoring site on AKAP79. Binding and inhibition of phosphatase activity are mediated by residues 315-360.Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney.

P2860

Q24309615-3F23192F-94FF-412C-975B-11BCE4C939C8 Q26800197-B5ADCDF5-ADC1-44DD-ABEA-2899F96DD4E2 Q27310102-BC048681-5F85-4E5E-8D38-05BBF09535F9 Q27935806-790F0550-D3B0-4F63-B304-B677F894BD2A Q28076325-F4DE4E13-FCDC-48AE-9FC3-5B9998E4A012 Q28505525-76401D6B-6F97-46E1-81B8-7798BB5F4C5E Q28568904-AE04E06E-B780-4733-84C2-A9FAA83B4318 Q28587028-33EB3CF9-2B84-424A-87AE-229938409DF9 Q28592216-70BFC1D3-F19C-413C-9D85-26659DFCD552 Q30491332-E8FEAAD5-E7BB-4C9D-B960-DF957EC0EC5D Q33668739-EA3FA95C-FA04-4C94-B9EA-B7F0EA4EF64C Q33713890-19248637-7773-4F65-B8EA-8D7E0EBF2E7D Q33925316-DAB0E2EA-FE78-4493-83CF-E0C91594C257 Q34020904-E1E1EC32-ABE1-4DC6-A490-FBC74807B652 Q34160636-33A5B8D9-AECA-4FA1-89DF-9C452A2FE442 Q34180391-4501627F-4EDE-41F0-82F6-9335A36425B4 Q34460234-2DA19615-50A7-4463-A1AB-83C94F1A31FE Q34581528-D394390E-CB23-45D9-B6E0-096667696C8A Q34584027-A54B16C8-E3DE-415C-9E74-7044B3AB94BE Q34641729-17EE0DCE-2A7F-40A1-B5E2-6A0A7E9BBECF Q34727513-436FB2B0-7E33-4910-A008-1D8FEACFF5F8 Q34882653-D3058EAA-30D1-4C62-BC04-C4AABF3D6C7F Q34901592-13C782E6-8FF1-489D-A02A-87B140D674C6 Q34974506-D1EBD926-3E06-41A0-A23D-D06CC2F9C4DE Q35098895-4C1FD3D1-99C2-447E-B683-EEB177671CA9 Q35201356-5F27418F-1E21-4D48-B580-39940E5BC49E Q36268310-F4B55DFA-137E-4067-8CF3-AFD4F3DBAA5B Q36302944-3D79631F-2DCC-4048-BACD-6D62E5FF97F1 Q36430063-32DE5A38-13FB-45FA-93EF-6F327EA557E4 Q36498375-23ED943F-9B29-41CE-ACAA-15E283C60347 Q36925323-7B4C0E78-1747-4A94-99C1-35EE38F72533 Q37129336-0E2A3363-3D4F-48E8-A276-67C97A744A20 Q37299072-C8C50355-9AE9-4C12-B890-466D99C4CB4E Q37332613-38C363CA-94D5-4B79-A026-72D106A0EB6D Q37414049-A83198C9-96DE-4A7A-A4D8-69E1096AC0CC Q37430992-253454D3-7EE8-4299-B1E5-84679168BC5F Q37510643-2BDF671C-6C40-4AC0-BB37-C4727CB3E1A3 Q37582043-92221C73-7AEE-4722-B32B-7159EEDE3A44 Q37704624-A50A1BC3-9920-4793-BA3F-5C9BA611F7C2 Q37908184-E30423D1-C0E2-4BFD-842C-A980F0049B8B

P2860

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

http://www.wikidata.org/entity/Q28360110

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@ast

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@en

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@nl

type

label

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@ast

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@en

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@nl

prefLabel

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@ast

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@en

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@nl

P1433

Q28360110-99BE17A4-ED1C-4E11-9222-66B5F520A30F

P1476

Q28360110-CC376454-F034-4202-A7CB-3240F03FC5D2

P2093

Q28360110-0FABBCF0-78EB-456B-983D-E58DEC5FE374

Q28360110-213DDDFF-0894-4DAA-9AAA-512307E09485

Q28360110-326109DC-08A0-4BC7-AFB0-765DEEFE4465

Q28360110-36849702-FC92-4F53-94B3-8D102F674262

Q28360110-39238CB2-EB0F-4959-BF45-05E40D62B902

Q28360110-6B61C02E-B8CA-4844-A52A-7CED7FE13D42

Q28360110-9CE096DF-5824-4A18-B684-CB50FB726178

Q28360110-A1408763-2A65-4C9F-ADA7-3E86EDDB519E

Q28360110-AB23AA49-D395-4DA4-A6FE-228215515FFD

Q28360110-EEBC1A45-1EB5-4697-836F-59E46ED3CC7A

P2860

Q28360110-05F8F8C3-E66F-4EE2-966F-DB5E048173E5

Q28360110-096937DC-53AF-42A7-80AC-B44C91CDCA8F

Q28360110-1149364E-FA27-402A-AB08-BD0A78F91BF5

Q28360110-17B6BE45-F309-417B-9F05-EF6EE832CB88

Q28360110-18743A79-BE3B-4042-9B59-85D1382C8996

Q28360110-1A2FD3AE-7D60-4192-946A-8BD6FD85F8BD

Q28360110-2169126D-02FA-45A4-A1A6-CE2B0E9D6453

Q28360110-251DF4BD-48CB-45BD-9894-BEB00DFABD4C

Q28360110-329C8667-A3BE-4765-8BC9-9F91D9B23303

Q28360110-395927A9-147F-4841-BBA7-383E5FA77A85

P304

Q28360110-8E215678-2D30-4140-AC1E-FDF42FFADBE6

P31

Q28360110-FB66B662-92F4-467D-A666-596D690F2FBE

P356

Q28360110-E20A2CA2-992D-4255-A393-DB3C967FEDC4

P407

Q28360110-0B29A406-4F89-4336-B8BB-C5F12CF8FD1E

P433

Q28360110-87778CD4-41DF-4170-AB64-51A5B7500807

P478

Q28360110-C843DDDD-DD89-4586-BB9D-3E97D9393464

P50

Q28360110-48A11538-A43E-4E0C-9681-CCCAD088990E

P577

Q28360110-F4F8D86F-81EF-4DFF-BFB2-BB077D3DC3A4

P5875

Q28360110-E2E9F351-060F-44E1-B19F-DBAA51162EDD

P698

Q28360110-17027467-CF5B-46E4-A7A8-0FF50DE40481

P932

Q28360110-6F32FDF8-E40F-4715-BCF7-EBD3586B245B

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo

@en

P2093

B J Glascock

http://www.w3.org/2001/XMLSchema#string

F del Monte

http://www.w3.org/2001/XMLSchema#string

H W Lim

http://www.w3.org/2001/XMLSchema#string

J C Braz

http://www.w3.org/2001/XMLSchema#string

L J De Windt

http://www.w3.org/2001/XMLSchema#string

O F Bueno

http://www.w3.org/2001/XMLSchema#string

Q Liang

http://www.w3.org/2001/XMLSchema#string

R J Hajjar

http://www.w3.org/2001/XMLSchema#string

T F Kimball

http://www.w3.org/2001/XMLSchema#string

U Delling

http://www.w3.org/2001/XMLSchema#string

P2860

Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes

Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways

DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways

A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling

Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT

Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2

A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

Association of protein kinase A and protein phosphatase 2B with a common anchoring protein

Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy

Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure

P304

3322-3327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.031371998

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Jeffery D. Molkentin

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12084456

http://www.w3.org/2001/XMLSchema#string

P698

11248077

http://www.w3.org/2001/XMLSchema#string

P932

30652

http://www.w3.org/2001/XMLSchema#string